SEC Form 4 · accession 0001674797-26-000006
CalciMedica, Inc. · CALC
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Evgeny Zaytsev
Director
Period of report
Aug 19, 2026
Accepted (ET)
Aug 21, 2026 · 6:44 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001534133
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| WarrantF3,F2 | $0.8033 | Aug 19, 2026 | A | 1,450,267 | A | Aug 19, 2026 | Dec 25, 2027 | Common Stock | 1,450,267 | 1,450,267 | I |
| WarrantF3,F4 | $1.00 | Aug 19, 2026 | A | 1,450,267 | A | Aug 19, 2026 | Jun 25, 2031 | Common Stock | 1,450,267 | 1,450,267 | I |
| Director Stock Option (Right to Buy)F5 | $0.6131 | Aug 19, 2026 | A | 10,000 | A | — | Aug 18, 2036 | Common Stock | 10,000 | 10,000 | D |
Explanation of responses
- F1The securities were acquired from the Issuer pursuant to a Securities Purchase Agreement dated June 23, 2026, with a closing date of June 25, 2026. The Securities Purchase Agreement and the issuance of the securities thereunder was approved by an independent committee of the Issuer's Board of Directors.
- F2The warrant may be exercised on or after August 19, 2026, and on or prior to the earlier of (i) December 25, 2027 and (ii) thirty (30) days following the Issuer's public disclosure of the clearance of its Investigational New Drug Application by the U.S. Food and Drug Administration for CM5480; provided, however, that the holder will be prohibited, subject to certain exceptions, from exercising such warrant for shares of common stock of the Issuer to the extent that immediately prior to or after giving effect to such exercise, the holder, together with its affiliates and other attribution parties, would own more than 9.99% of the total number of shares of common stock of the Issuer then issued and outstanding, which percentage may be changed at the holder's election to a lower percentage at any time or to a higher percentage upon 61 days' notice to the Issuer.
- F3The securities are held by Bering Partners II, L.P. ("Bering II"). Bering Partners II GP, L.L.C. ("Bering II GP") is the general partner of Bering II and may be deemed to have voting and dispositive power over the securities held by Bering II. The Reporting Person, a member of the Issuer's board of directors, and Philip Sawyer are the managing members of Bering II GP and may be deemed to have voting and dispositive power with respect to these securities. Each of Bering II GP, the Reporting Person and Mr. Sawyer disclaim beneficial ownership of the securities held by Bering II, except to the extent of such person's pecuniary interest therein.
- F4The warrant may be exercised on or after August 19, 2026 and on or prior to June 25, 2031; provided, however, that the holder will be prohibited, subject to certain exceptions, from exercising such warrant for shares of common stock of the Issuer to the extent that immediately prior to or after giving effect to such exercise, the holder, together with its affiliates and other attribution parties, would own more than 9.99% of the total number of shares of common stock of the Issuer then issued and outstanding, which percentage may be changed at the holder's election to a lower percentage at any time or to a higher percentage upon 61 days' notice to the Issuer.
- F51/12th of the shares subject to the option vest in equal monthly installments over a one year period following the date of grant, provided that the option will in any case be fully vested on the date of the 2027 annual meeting of stockholders of CalciMedica, Inc.